Max India Limited Investor Release

Quarter and Nine months ended December 31, 2018

Disclaimer

This release is a compilation of financial and other information all of which has not been subjected to audit and is not a statutory release. This may also contain statements that are forward looking. These statements are based on current expectations and assumptions that are subject to risks and uncertainties. Actual results could differ materially from our expectations and assumptions. We do not undertake any responsibility to update any forward looking statements nor should this be constituted as a guidance of future performance.







Max India – Key Highlights (Q3FY19)


1 Max Healthcare to merge with Radiant: Applications filed with CCI and RBI. Filing with IRDAI, SEBI and NCLT thereafter. Expected completion 9-12 months

- 2 Max Healthcare : Net revenue grows 3% to Rs 677 Cr. EBITDA grows 11% y-o-y to Rs. 63 Cr; margins improve to 9.2%, up 67 bps sequentially
- *Max Bupa:* Gross Premium grows 25% to Rs 223 Cr; Net loss at Rs 16 Cr vs. Rs 5 Cr in PY. Normalising for reinsurance, net loss is Rs 19 Cr vs Rs 21 Cr in PY
- 4 **Max Bupa:** HDFC Bank Telesales business launched in Q3; Corporate agency activated with HDFC securities
 - 5

Antara: Antara to set up second project in New Chandigarh via an asset light model



MHC Network* (Financial Snapshot – Q3FY19)



*The above results are for MHC Network of hospitals, includes results for Max Super Specialty Hospital, Saket, unit of Devki Devi Foundation, Max Super Speciality Hospital, Patparganj, unit of Balaji Medical and Diagnostic Research Centre; Saket City Hospital unit of Gujarmal Modi Hospital & Research Centre and Max Multi Speciality Hospital Greater Noida unit of Four Season Foundation


MHC Network* – Performance Dashboard (Q3 & 9MFY19)

Kay Business Drivers	Quarter	⁻ Ended	Y-o-Y	Nine months Ended		Y-o-Y
Key Business Drivers	Dec-18	Dec-17	Growth	Dec-18	Dec-17	Growth
a) Financial Performance						
Revenue (Gross)	738	703	5%	2,158	2,116	2%
Revenue (Net)	677	656	3%	1,988	1,998	0%
Direct Costs						
Material Cost	168	162	4%	498	497	0%
Clincian Payout	112	116	-4%	332	350	-5%
Contribution	398	378	5%	1,158	1,151	1%
Contribution Margin^	58.7%	57.7%	107 bps	58.2%	57.6%	63 bps
Indirect Costs						
Personnel Cost	189	173	9%	557	510	9%
Other Indirect overheads	111	120	-8%	342	352	-3%
HO Costs	36	29	22%	101	99	2%
EBITDA	63	56	11%	157	189	-17%
EBITDA Margin^	9.2%	8.6%	67 bps	7.9%	9.5%	(156) bps
Finance Cost	35	35	-1%	96	99	-3%
Cash Profit	27	21	32%	62	90	-32%
Depreciation	35	34	1%	110	102	8%
Profit /(loss) before tax	(7)	(14)	46%	(49)	(11)	-326%
Тах	-	1	0%	3	3	0%
Profit /(loss) after tax	(7)	(14)	49%	(51)	(15)	-251%
b) Financial Position						
Net Worth	1,031	1,106	-7%	1,031	1,106	-7%
Net Debt	1,272	1,190	7%	1,272	1,190	7%
Tangible Fixed Assets - Gross Block	2,220	2,053	8%	2,220	2,053	8%



*The above results are for MHC Network of hospitals and includes results for Max Super Specialty Hospital, Saket, unit of Devki Devi Foundation, Max Super Speciality Hospital, Patparganj, unit of Balaji Medical and Diagnostic Research Centre ; Saket City Hospital unit of Gujarmal

Modi Hospital & Research Centre & Max Multi Speciality Hospital Greater Noida unit of Four Season Foundation





Rs Cr

MHC Network* – Performance Dashboard (Q3 & 9MFY19)

	Quarter	Ended	Y-o-Y	Nine months Ended		Y-o-Y
Key Business Drivers	Dec-18	Dec-17	Growth	Dec-18	Dec-17	Growth
a) Patient Transactions (Nos in lacs)						
Inpatient Discharges	0.46	0.51	-10%	1.42	1.55	-8%
Day care Procedures	0.12	0.12	1%	0.34	0.38	-9%
Outpatient Footfalls	16.83	16.05	5%	51.77	50.94	2%
Total	17.41	16.68	4%	53.53	52.87	1%
b) Average Inpatient Operational Beds	2,383	2,353	1%	2,379	2,319	3%
c) Average Inpatient Occupancy	74.2%	74.3%	(11) bps	73.1%	74.4%	(129) bps
d) Average Length of Stay (days)	3.39	3.13	-9%	3.37	3.05	-10%
e) Average Revenue/Occupied Bed Day (Rs)	43,881	43,425	1%	43,770	41,187	6%
f) Other Operational Data						
Physicians				3,136	2,862	10%
Employees				9,715	9,171	6%
Customer Base (in lacs)				43.9	40.7	8%



*The above results are for MHC Network of hospitals, includes results for Max Super Specialty Hospital, Saket, unit of Devki Devi Foundation, Max Super Speciality Hospital, Patparganj, unit of Balaji Medical and Diagnostic Research Centre; Saket City Hospital unit of Gujarmal Modi Hospital & Research Centre and Max Multi Speciality Hospital Greater Noida unit of Four Season Foundation



MHC Network Hospitals (Saket* & East Delhi[^] Complex) - Performance Dashboard (Q3 & 9MFY19)

							Rs Cr
Key Business Drivers	Unit	Quarter	Quarter Ended		Nine months ended		Y-o-Y
Rey Dusiness Drivers		Dec-18	Dec-17	Growth	Dec-18	Dec-17	Growth
Saket Complex							
a) Financial Performance							
Revenue(Net)	Rs. Cr	250	247	1%	741	760	-2%
EBITDA	Rs. Cr	24	29	-14%	73	91	-19%
EBITDA Margin	%	9.8%	11.5%	(173) bps	9.9%	11.9%	(203) bps
b) Average Inpatient Operational Beds	No.	768	758	1%	769	738	4%
c) Average Inpatient Occupancy	%	74.5%	75.5%	(101) bps	73.8%	76.4%	(254) bps
d) Average Revenue/Occupied Bed Day	Rs.	52,944	50,598	5%	52,314	51,861	1%
e) Average Length of Stay		3.66	3.38	-8%	3.65	3.28	-11%
East Delhi Complex							
a) Financial Performance							
Revenue(Net)		184	174	5%	532	511	4%
EBITDA	Rs. Cr	28	23	20%	67	64	4%
EBITDA Margin	%	15.2%	13.3%	187 bps	12.5%	12.6%	(5) bps
b) Average Inpatient Operational Beds	No.	702	716	-2%	698	696	0%
c) Average Inpatient Occupancy	%	82.2%	79.0%	327 bps	80.4%	78.3%	209 bps
d) Avg. Revenue/Occupied Bed Day	Rs.	37,779	36,675	3%	37,900	36,992	2%
e) Average Length of Stay	(days)	3.71	3.13	-18%	3.61	3.06	-18%



*Saket Complex includes Saket West Block, Saket East Block (unit of Devki Devi Foundation) & Max Smart (unit of Smart Hospital & Research Centre) hospital

^East Delhi Complex includes Max Patparganj (unit of Balaji Medical and Diagnostic Research Centre) & Max Vaishali hospital

MAX INDIA LIMITED 5

Max Bupa (Financial Snapshot – Q3 & 9MFY19)

Revenue	 Gross Written Premium (GWP) for Q3FY19 grows 25% to Rs. 223 Cr, driven by 40% growth in new sales and 17% growth in renewals. Average premium realisation (B2C segment) for Q3FY19 at Rs 8,031 grows 3% y-o-y Urban lives-in-force crosses 2.3 million, ~ 603K lives covered in Q3FY19 Conservation ratio (B2C) for Q3FY19 at 86%, improved by 491 bps over PY HDFC Bank - Telesales business launched in Q3; Corporate agency activated with HDFC securities
Profitability / Others	 Net loss at Rs 16 Cr in Q3FY19 vs Rs 5 Cr in PY. Normalising for reinsurance impact net loss is Rs 19 Cr in Q3FY19 vs Rs 21 Cr in PY. B2C claims ratio for the quarter at 55%, improved by 270 bps over PY
Award and Accolades	 Recognized 3rd time as a Superbrand in 2018 Won 'The Assocham Brand Science 2018 and Excellence Awards' under the category of 'Best Innovative Brand'





Max Bupa – Performance Dashboard (Q3 & 9MFY19)

Kou Rusinoss Drivors	Quarter Ended		Y-o-Y	Nine months Ended		Y-o-Y
Key Business Drivers	Dec-18	Dec-17	Growth	Dec-18	Dec-17	Growth
a) Gross written premium income						
First year premium	86	61	40%	228	169	35%
Renewal premium	137	117	17%	399	336	19%
Total	223	178	25%	627	505	24%
b) Net Earned Premium	188	151	24%	532	429	24%
c) Cash Profit /(Loss)	(12)	(1)	< -100%	(43)	2	< -100%
d) Pre tax Profit /(Loss)	(16)	(5)	< -100%	(55)	(10)	<-100%
e) Claim Ratio (B2C Segment, normalized)*	55%	58%	270bps	52%	58%	590 bps
f) Avg. premium realization per life (B2C)	8,031	8,057	0%	8,224	8,011	3%
g) Conservation ratio (B2C Segment)	86%	81%	491 bps	85%	82%	323 bps
h) Lives In force in millions (including RSBY)				3.4	2.6	31%
i) Number of agents				29,703	23,712	25%
j) Paid up Capital				969	926	5%





Disclaimer

This presentation has been prepared by Max India Limited (the "Company"). No representation or warranty, express or implied, is made and no reliance should be placed on the accuracy, fairness or completeness of the information presented or contained in the presentation. The past performance is not indicative of future results. Neither the Company nor any of its affiliates, advisers or representatives accepts liability whatsoever for any loss howsoever arising from any information presented or contained in the presentation. The information presented or contained in these materials is subject to change without notice and its accuracy is not guaranteed.

The presentation may also contain statements that are forward looking. These statements are based on current expectations and assumptions that are subject to risks and uncertainties. Actual results could differ materially from our expectations and assumptions. We do not undertake any responsibility to update any forward looking statements nor should this be constituted as a guidance of future performance.

This presentation does not constitute a prospectus or offering memorandum or an offer to acquire any securities and is not intended to provide the basis for evaluation of the securities. Neither this presentation nor any other documentation or information (or any part thereof) delivered or supplied under or in relation to the securities shall be deemed to constitute an offer of or an invitation.

No person is authorised to give any information or to make any representation not contained in and not consistent with this presentation and, if given or made, such information or representation must not be relied upon as having been authorised by or on behalf of the Company any of its affiliates, advisers or representatives.

The Company's Securities have not been and are not intended to be registered under the United States Securities Act of 1993, as amended (the "Securities Act"), or any State Securities Law and unless so registered may not be offered or sold within the United States or to, or for the benefit of, U.S. Persons (as defined in Regulations S under the Securities Act) except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and the applicable State Securities Laws.

This presentation is highly confidential, and is solely for your information and may not be copied, reproduced or distributed to any other person in any manner. Unauthorized copying, reproduction, or distribution of any of the presentation into the U.S. or to any "U.S. persons" (as defined in Regulation S under the Securities Act) or other third parties (including journalists) could prejudice, any potential future offering of shares by the Company. You agree to keep the contents of this presentation and these materials confidential.



MAX INDIA LTD.

Max House, Okhla, New Delhi – 110 020 Phone: +91 11 26933601-10 Fax: +91 11 26933619 Website: www.maxindia.com

